Weednesday September 23 2020
HAPPY HEMP DAY1 In todays report:
Click here for the link to the video on youtube
Oregon Marijuana Businesses Impacted By Wildfires Are Ineligible For Federal Relief, Agency Confirms
“Marijuana businesses are not eligible to apply for SBA disaster loans,” SBA spokesperson Carol Chastang said, adding that the relief also doesn’t extend to agriculture businesses so even hemp farmers don’t qualify regardless of the crop’s legal status.
That said, people who work in either the marijuana or hemp market whose primary residence is damaged or destroyed by the fires can apply.
Relief for the industry is seriously needed amid the rampant wildfires. According to the Oregon Liquor Control Commission, 20 percent of marijuana businesses in the state have been encouraged to evacuate. Regulators are also asking cannabis business owners to fill out a survey so they can get a better sense of how extensive the damage is.
Last month, the state saw about $106 million in medical and recreational cannabis sales, marking the third month in a row that sales exceeded $100 million. That’s according to a recent report from the Oregon Liquor Control Commission (OLCC).
https://www.marijuanamoment.net/oregon-marijuana-sales-break-another-record-amid-coronavirus/
FDA Explains Effects Of CBD And Marijuana Compounds Based On Sex And Gender Differences
Food and Drug Administration (FDA) announced on Tuesday that it will be hosting a public meeting in November to discuss gender and sex differences in the effects of CBD and other cannabinoids.
said.
“Researchers, educators, clinicians, and patients may benefit from attending this multidisciplinary scientific conference on CBD and other cannabinoids,” FDA said. “Presentations will address patient and healthcare provider perspectives on CBD and other cannabinoid use, sex differences in the effects of CBD and other cannabinoids, use of CBD and other cannabinoids in pregnancy, and government agency perspectives on CBD research and evaluation.”
“Conditions for which CBD is often marketed, such as chronic pain, anxiety, depression, and sleep disturbances, are more prevalent in women than men,” FDA said in its Federal Register notice. “Therefore, consideration of issues pertaining to the safety of CBD products may be particularly important to address in women.”
decisions.”
FDA has been using enforcement discretion for CBD in the years since hemp became legal.
The agency has continued to issue warnings to cannabis businesses in certain cases—such as instances in which companies claimed CBD could treat or cure coronavirus—and provide public notices about recalls.
New FDA Guidance Will Make It Easier To Approve CBD-Based Medicines
To expedite the approval process, FDA said applicants can request a waiver of an in vivo bioequivalence study if they meet certain requirements. This guidance comes two years after the agency approved the brand-name CBD-based epilepsy medication Epidiolex from GW Pharmaceuticals.
Researchers must use “appropriate analytical methods” such as macroscopic or microscopic analysis or DNA bar-coding methods to determine that the solution is being made from cannabis sativa.
A public comment period on FDA’s draft guidance will last until November 23. FDA also recently closed a comment period on separate draft guidance on developing cannabis-
The agency was mandated under appropriations legislation enacted late last year to provide an update on its regulatory approach to CBD, and it did so in March. The update stated that “FDA is currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors FDA intends to take into account in prioritizing enforcement decisions.” my
The Food and Drug Administration (FDA) is releasing new draft guidelines that are meant to streamline approvals for generic oral CBD medications.
In a notice published in the Federal Register on Wednesday, the agency said it is soliciting public feedback on its guidance to researchers who are interested in submitting abbreviated new drug applications (ANDAs) for CBD solutions.
https://www.marijuanamoment.net/new-fda-guidance-will-make-it-easier-to-approve-cbd-based-medicines/